Background
Methods
Search strategy
Selection criteria
Data extraction and quality assessment
Statistical analysis
Results
Study characteristics
Study | Nation | Research type | Time data collected | Sampling frame | Follow-up time | Stone types | Race | Age | Sample size | Man (%) | Recurrence rate (%) | Ratio |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Song et al. [16] | USA | Retrospective | 2007–2013 | SC | Median 64 m | NA | Mixed | Mean 57.6 | 14,854 | 93.81 | 57.60 | HR |
Ito et al. [17] | Japan | Retrospective | 2012–2019 | SC | Median 31 m | Mixed | Asian | Mean 60.0 | 664 | 63.00 | 20.33 | HR |
Iremashvili et al. [18] | USA | Retrospective | 2009–2017 | SC | Mean 4.3 y | NA | Mixed | Mean 54.9 | 1,970 | 51.62 | 20.96 | HR |
Samson et al. [19] | USA | Retrospective | 2007–2017 | SC | 3 y | NA | Mixed | Mean 46.0 | 434,055 | 57.69 | 14.50 | OR |
Prasanchaimontri and Monga [20] | USA | Retrospective | 2002–2012 | SC | Median 10 y | Mixed | Mixed | NA | 1,617 | 62.71 | 23.07 | OR |
Nevo et al. [21] | Israel | Retrospective | 2010–2015 | SC | Median 38 m | Mixed | Caucasian | Median 53 | 457 | 69.20 | 24.29 | HR |
Islam et al. [22] | USA | Retrospective | 2008–2018 | SC | 10 y | NA | Mixed | Mean 57.6 | 69 | 44.93 | 23.19 | OR |
Ingvarsdottir et al. [23] | Iceland | Retrospective | 1985–2013 | SC | Median 12 y | Mixed | Caucasian | Median 15 | 190 | 41.05 | 35.79 | HR |
Castiglione et al. [24] | USA | Prospective | 2009 | SC | 5 y | NA | Mixed | Mean 48.2 | 375 | 54.80 | 21.07 | OR |
Vaughan et al. [25] | USA | Retrospective | 1984–2012 | SC | NA | NA | Mixed | Mean 43.9 | 3,364 | 60.79 | 26.22 | HR |
Kang et al. [26] | Korea | Retrospective | 1994–2017 | SC | 15 years | NA | Asian | Mean 49.1 | 680 | 60.15 | 41.18 | HR |
Iremashvili et al. [27] | USA | Retrospective | 2009–2016 | SC | Median 4.8 y | NA | Mixed | Mean 53.6 | 498 | 52.21 | 17.67 | HR |
Iremashvili et al. [28] | USA | Retrospective | 2009–2017 | SC | Mean 4.1 y | NA | Mixed | Mean 54.8 | 1,496 | 52.07 | 24.53 | HR |
Ruysscher et al. [29] | Belgium | Retrospective | 1998–2016 | SC | NA | NA | Caucasian | Median 3.9 | 97 | 73.20 | 34.02 | OR |
Costa et al. [30] | USA | Prospective | 2009–2013 | SC | 5 y | Mixed | Mixed | Mean 49.6 | 175 | 53.14 | 66.86 | OR |
Yamashita et al. [31] | Japan | Retrospective | 2011–2015 | SC | NA | NA | Asian | Median 59 | 300 | 69.33 | 49.33 | OR |
Wang et al. [32] | China | Retrospective | 2015 | SC | NA | COS | Asian | mean 50.6 | 72 | 75.00 | 50.00 | OR |
Ozgor et al. [33] | Turkey | Retrospective | 2011–2013 | SC | Mean 33.3 m | Mixed | Caucasian | Mean 47.33 | 202 | 53.11 | 22.28 | OR |
Ferraro et al. [34] | Italy | Prospective | 1993–1994 | SC | 5 y | COS | Caucasian | Mean 45.3 | 103 | NA | 33.98 | HR |
Tasian et al. [6] | USA | Retrospective | 2008–2014 | SC | 3 y | Mixed | Caucasian | Median 14.8 | 285 | 45.61 | 23.86 | HR |
Kang et al. [35] | Korea | Retrospective | 1994–2015 | SC | NA | Mixed | Asian | Mean 44.9 | 624 | 63.58 | 37.66 | HR |
Shih et al. [36] | China | Retrospective | 2000–2002 | SC | Mean 8.9 y | NA | Asian | Mean 27.48 | 1,474 | 0.00 | 16.62 | HR |
Guerra et al. [37] | Italian | Retrospective | 1986–2013 | SC | NA | CS | Caucasian | NA | 2,080 | 61.01 | 6.11 | OR |
El-Assmy et al. [38] | Egypt | Retrospective | 1998–2011 | SC | 10 y | Mixed | Caucasian | Mean 41.3 | 784 | 73.09 | 25.26 | HR |
Bos et al. [39] | Canada | Prospective | 2009–2010 | SC | 5 y | NA | Caucasian | Mean 54.5 | 110 | 63.64 | 25.45 | HR |
Liu et al. [40] | China | Retrospective | 1999–2010 | SC | NA | NA | Asian | Mean 52.8 | 1,259 | 85.94 | 13.26 | HR |
Rule et al. [41] | USA | Retrospective | 1984–2003 | SC | NA | Mixed | Mixed | Mean 41.7 | 2,239 | 62.48 | 31.58 | HR |
Kang et al. [42] | Korea | Retrospective | 1994–2010 | SC | Median 35 m | Mixed | Asian | NA | 240 | NA | 23.33 | HR |
Kang et al. [43] | Korea | Retrospective | 2007–2011 | SC | NA | Mixed | Asian | Mean 60.4 | 342 | 48.25 | 16.96 | HR |
Kruck et al. [44] | Germany | Retrospective | 2001–2007 | SC | NA | Mixed | Caucasian | Mean 51.5 | 482 | 66.00 | NA | OR |
Kohjimoto et al. [45] | Japan | Retrospective | 2005 | MC | 7 y | Mixed | Asian | Mean 52.5 | 11,555 | 73.86 | 57.14 | OR |
Sorensen et al. [46] | USA | Retrospective | 2001–2010 | SC | NA | NA | Caucasian | Mean 55 | 40 | 32.50 | 22.50 | OR |
Pieras et al. [47] | Spain | Retrospective | 2003–2007 | SC | Mean 60 m | Mixed | Caucasian | Mean 44 | 248 | 69.76 | 48.79 | HR |
Ha et al. [48] | Korea | Retrospective | 1994–2008 | SC | NA | CS | Asian | NA | 247 | NA | 39.68 | HR |
DeFoor et al. [49] | USA | Retrospective | 1999–2006 | SC | NA | Mixed | Mixed | Mean 12.7 | 139 | 52.52 | 36.69 | OR |
Kim et al. [50] | Korea | Retrospective | 1994–2007 | SC | Median 49 m | CS | Asian | mean 44.3 | 266 | 65.20 | 41.73 | HR |
Lee et al. [51] | Korea | Retrospective | 1996–2006 | SC | Median 54 m | Mixed | Asian | Mean 42.9 | 163 | 66.76 | 36.20 | HR |
Krambeck et al. [52] | USA | Retrospective | 1983–1984 | SC | > 5 y | Mixed | Mixed | NA | 375 | 64.80 | 49.60 | OR |
Unal et al. [53] | Turkey | Retrospective | NA | SC | NA | NA | Caucasian | Mean 35 | 173 | 50.87 | 28.32 | HR |
Daudon et al. [54] | France | Retrospective | 1984–2000 | SC | 3 y | COS | Caucasian | Mean 30.4 | 181 | 70.17 | 39.78 | HR |
Abe et al. [55] | Japan | Retrospective | 1987–2000 | SC | 5 y | Mixed | Asian | Mean 45.7 | 11,39 | 72.10 | 28.62 | OR |
Parks et al. [56] | USA | Prospective | 1970–2003 | SC | 30 y | ICN | Mixed | Mean 33.0 | 1,201 | 70.86 | NA | HR |
Mardis et al. [57] | USA | Prospective | 1995–1996 | SC | 7 y | Mixed | Mixed | NA | 203 | 70.44 | 29.06 | HR |
Afshar et al. [58] | Canada | Retrospective | 1990–2002 | SC | Mean 46 m | Mixed | Caucasian | Mean 7 | 83 | 46.99 | 31.33 | OR |
Siener et al. [59] | Germany | Prospective | NA | SC | 2 y | COS | Caucasian | Mean 51.7 | 134 | 67.16 | 42.54 | OR |
Chen et al. [60] | USA | Retrospective | 1973–1996 | SC | 5 y | NA | Mixed | Mean 37 | 62 | 87.10 | 30.65 | RR |
Borghi et al. [61] | Italy | Prospective | 1993–1994 | SC | 5 y | COS | Caucasian | Mean 45.1 | 120 | 100.00 | 43.33 | RR |
Jendle-Bengten et al. [62] | Sweden | Retrospective | NA | SC | Mean 5.6 y | COS | Caucasian | Mean 50 | 52 | 73.08 | 51.92 | HR |
Trinchieri et al. [63] | Italy | Prospective | 1980–1990 | SC | Mean 19.3 y | Mixed | Caucasian | Mean 44.3 | 195 | 50.26 | 26.67 | HR |
Ettinger et al. [64] | USA | Prospective | NA | SC | 3 y | COS | Mixed | Mean 48.0 | 64 | 78.13 | 39.06 | RR |
Hiatt et al. [65] | USA | Prospective | 1984–1985 | MC | 4.5 y | COS | Mixed | Mean 43.0 | 99 | 78.79 | 14.14 | HR |
Gambaro et al. [66] | Italy | Prospective | 1984–1986 | SC | 9 y | NA | Caucasian | Median 34 | 190 | 65.79 | 57.89 | OR |
Streem [67] | USA | Prospective | 1983 | SC | Mean 41.7 m | MAPS | Mixed | Mean 53.2 | 44 | 20.45 | 27.27 | OR |
Quality assessment
Demographic risk factors
Risk factors | No. of studies | No. of patients | OR (95% CI) | P value | Model | Heterogeneity | |
---|---|---|---|---|---|---|---|
I2(%) | P | ||||||
Demographic risk factors | |||||||
Age | 18 | 28,315 | 0.980 (0.966–0.995) | 0.009# | Random | 84.7 | < 0.001§ |
BMI | 16 | 22,087 | 1.045 (1.008–1.083) | 0.016* | Random | 62.4 | < 0.001§ |
Sex | 23 | 41,466 | 1.046 (0.945–1.157) | 0.388 | Random | 65.8 | < 0.001§ |
Race | 3 | 4,707 | 1.338 (1.033–1.732) | 0.027* | Fixed | 0.0 | 0.982 |
Pregnant or childbirth | 2 | 3,609 | 0.896 (0.228–3.525) | 0.875 | Random | 96.8 | < 0.001§ |
Gout | 3 | 18,083 | 1.181 (0.745–1.871) | 0.479 | Random | 79.4 | 0.008# |
Diabetes | 5 | 29,938 | 1.095 (0.959–1.251) | 0.179 | Random | 56.3 | 0.058 |
Hypertension | 5 | 29,938 | 1.126 (1.076–1.178) | < 0.001§ | Fixed | 0.0 | 0.579 |
Hyperlipidemia | 3 | 13,114 | 1.020 (0.670–1.553) | 0.925 | Random | 74.4 | 0.020* |
Osteoporosis | 2 | 16,113 | 1.140 (0.743–1.749) | 0.550 | Random | 52.5 | 0.147 |
Urinary tract anomalies | 2 | 178 | 1.098 (0.274–4.405) | 0.895 | Random | 65.8 | 0.087 |
Kidney stone-related risk factors | |||||||
Family history of kidney stones | 12 | 11,912 | 1.194 (1.078–1.323) | 0.001# | Random | 46.8 | 0.037* |
Personal history of kidney stones | 11 | 10,784 | 1.428 (1.230–1.658) | < 0.001§ | Random | 52.1 | 0.022* |
Any gross hematuria with first symptomatic stone | 2 | 2,737 | 1.068 (0.893–1.276) | 0.473 | Fixed | 0.0 | 0.324 |
Suspected kidney stone episodea prior to first confirmed stone episode | 3 | 6,101 | 1.815 (1.559–2.114) | < 0.001§ | Fixed | 0.0 | 0.802 |
Any concurrent asymptomatic (nonobstructing) stone | 2 | 2,737 | 1.711 (1.464–1.999) | < 0.001§ | Fixed | 2.0 | 0.312 |
Uric acid stone | 4 | 4,602 | 1.957 (1.414–2.707) | < 0.001§ | Fixed | 40.0 | 0.172 |
Calcium oxalate monohydrate | 2 | 3,612 | 0.897 (0.785–1.025) | 0.110 | Fixed | 0.0 | 0.331 |
Calcium phosphate stone | 2 | 1,865 | 1.271 (0.592–2.731) | 0.538 | Fixed | 37.2 | 0.207 |
Diameter of largest kidney stone | 8 | 3,771 | 1.047 (0.995–1.101) | 0.076 | Random | 74.4 | < 0.001§ |
Multiple calculi | 4 | 1,760 | 1.338 (0.965–1.855) | 0.080 | Random | 80.3 | 0.002# |
Bilateral nephrolithiasis | 2 | 2,218 | 2.175 (0.860–5.500) | 0.101 | Random | 82.2 | 0.018* |
Pelvic or lower pole kidney stone | 3 | 6,101 | 1.666 (1.264–2.195) | < 0.001§ | Random | 76.6 | 0.014* |
Ureteral stone | 2 | 1,387 | 0.888 (0.380–2.075) | 0.785 | Random | 85.7 | 0.008# |
Ureterovesical junction stone | 3 | 6,101 | 0.845 (0.761–0.937) | 0.001# | Fixed | 0.0 | 0.439 |
Treatment method risk factors | |||||||
Stone prevention medications | 9 | 4,316 | 0.752 (0.548–1.033) | 0.078 | Random | 76.0 | < 0.001§ |
Potassium citrate | 4 | 2,992 | 0.732 (0.345–1.554) | 0.417 | Random | 87.7 | < 0.001§ |
Surgery | 3 | 8,23 | 2.161 (1.557–2.998) | < 0.001§ | Fixed | 0.0 | 0.457 |
ESWl | 4 | 1,495 | 1.756 (0.606–5.086) | 0.299 | Random | 93.9 | < 0.001§ |
24-h urine and serum tests related risk factors | |||||||
Baseline urine volume | 6 | 1,789 | 0.934 (0.756–1.154) | 0.528 | Random | 64.0 | 0.016* |
Baseline urine calcium | 8 | 2,552 | 1.001 (0.997–1.005) | 0.531 | Random | 55.9 | 0.026* |
Baseline low urine citrate | 7 | 2,371 | 1.000 (0.998–1.002) | 0.994 | Random | 55.6 | 0.035* |
Baseline urine oxalate | 7 | 2,371 | 0.999 (0.993–1.004) | 0.675 | Fixed | 26.3 | 0.228 |
Baseline urine sodium | 4 | 1,719 | 1.001 (0.999–1.002) | 0.325 | Fixed | 0.0 | 0.563 |
Baseline urine uric acid | 6 | 2,232 | 1.000 (0.999–1.001) | 0.992 | Random | 51.1 | 0.069 |
Baseline urine magnesium | 3 | 1,095 | 1.081 (0.777–1.503) | 0.645 | Fixed | 0.0 | 0.780 |
Baseline urine phosphate | 2 | 422 | 0.978 (0.315–3.038) | 0.969 | Random | 89.4 | 0.002# |
Baselin urine osmolality | 2 | 855 | 1.257 (0.629–2.515) | 0.517 | Random | 83.3 | 0.014* |
CaOx SS (DG) | 2 | 314 | 0.808 (0.611–1.068) | 0.134 | Fixed | 0.0 | 0.972 |
Serum calcium | 2 | 348 | 1.033 (0.787–1.356) | 0.817 | Fixed | 0.0 | 0.790 |
GFR | 3 | 1,094 | 1.017 (0.963–1.074) | 0.539 | Random | 92.3 | < 0.001§ |
24 h urine test completion | 2 | 448,909 | 1.157 (1.128–1.186) | < 0.001§ | Fixed | 0.0 | 0.519 |
Kidney stone-related risk factors
Treatment method related risk factors
Stone prevention medications
Surgery versus conservative treatment
ESWL versus other treatment
24-h urine and serum tests related risk factors
Other risk factors
Subgroup analysis
Risk factors | No. of studies | No. of patients | OR (95% CI) | P value | Model | Heterogeneity | |
---|---|---|---|---|---|---|---|
I2 (%) | P | ||||||
Demographic risk factors | |||||||
Age | 6 | 5,020 | 0.996 (0.971–1.022) | 0.762 | Random | 79.5 | < 0.001§ |
BMI | 9 | 15,473 | 1.062 (1.015–1.111) | 0.009# | Random | 63.6 | 0.005# |
Sex | 12 | 16,245 | 1.128 (0.976–1.305) | 0.104 | Random | 56.6 | 0.008# |
Urinary tract anomalies | 2 | 178 | 1.098 (0.274–4.405) | 0.895 | Random | 65.8 | 0.087 |
Kidney stone-related risk factors | |||||||
Family history of kidney stones | 6 | 1,692 | 1.089 (0.966–1.227) | 0.162 | Fixed | 0.0 | 0.830 |
Personal history of kidney stones | 5 | 2,506 | 1.402 (1.239–1.587) | < 0.001§ | Fixed | 0.0 | 0.426 |
Diameter of largest kidney stone | 4 | 2,553 | 1.014 (0.999–1.029) | 0.059 | Fixed | 38.5 | 0.181 |
Multiple calculi | 4 | 1,760 | 1.338 (0.965–1.855) | 0.080 | Random | 80.3 | 0.002# |
Treatment method risk factors | |||||||
Stone prevention medications | 4 | 2,190 | 0.674 (0.421–1.079) | 0.100 | Random | 82.6 | 0.001# |
Potassium citrate | 3 | 1733 | 0.529 (0.221–1.255) | 0.148 | Random | 88.4 | < 0.001§ |
Surgery | 2 | 159 | 3.178 (1.597–6.322) | 0.001# | Fixed | 0.0 | 0.951 |
ESWl | 3 | 1,120 | 1.825 (0.386–8.615) | 0.448 | Random | 94.1 | < 0.001§ |
24-h urine and serum tests related risk factors | |||||||
Baseline urine volume | 6 | 1,789 | 0.934 (0.756–1.154) | 0.528 | Random | 64.0 | 0.016* |
Baseline urine calcium | 7 | 2,413 | 1.001 (1.000–1.002) | 0.224 | Fixed | 28.4 | 0.209 |
Baseline low urine citrate | 6 | 2,232 | 1.000 (1.000–1.000) | 1.000 | Fixed | 0.0 | 0.826 |
Baseline urine oxalate | 6 | 2,232 | 0.999 (0.993–1.004) | 0.690 | Fixed | 32.7 | 0.190 |
Baseline urine sodium | 4 | 1,719 | 1.001 (0.999–1.002) | 0.325 | Fixed | 0.0 | 0.563 |
Baseline urine uric acid | 6 | 2,232 | 1.000 (0.999–1.001) | 0.992 | Fixed | 51.4 | 0.069 |
Baseline urine magnesium | 3 | 1,095 | 1.081 (0.777–1.503) | 0.645 | Fixed | 0.0 | 0.780 |
Baseline urine phosphate | 2 | 422 | 0.978 (0.315–3.038) | 0.969 | Random | 89.4 | 0.002# |
Baselin urine osmolality | 2 | 855 | 1.257 (0.629–2.515) | 0.517 | Random | 83.3 | 0.014* |
Serum calcium | 2 | 348 | 1.033 (0.787–1.356) | 0.817 | Fixed | 0.0 | 0.790 |
GFR | 2 | 1,022 | 1.505 (0.656–3.453) | 0.335 | Random | 95.9 | < 0.001§ |